Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Trial Profile

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Head and neck cancer; Salivary gland cancer; Skin cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 13 Jul 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 13 Jul 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top